A Safety Study of 212Pb-Pentixather Radioligand Therapy
Status:
Not yet recruiting
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment
(Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously
treated, for atypical carcinoid lesions of the lung.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yusuf Menda
Collaborators:
Holden Comprehensive Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)